Arcus Biosciences CAO Azoy sells $84,810 in stock

Alexander Azoy, the Chief Accounting Officer at Arcus Biosciences, Inc., sold 2,827 shares of the company's common stock on August 21, 2026, as per a regulatory filing. The sale, conducted under a Rule 10b5-1 trading plan, took place at a price of $30.0 per share, resulting in a total of $84,810. This transaction occurred as Arcus stock hovered close to its 52-week high of $31.73, following an impressive 186% increase over the past year.

However, InvestingPro analysis suggests that the stock might be slightly overvalued at its current level in relation to its estimated Fair Value. The platform highlights that four analysts have raised their earnings projections for the next period, contributing to 14 key ProTips available to subscribers. Following these sales, Mr. Azoy remains the direct owner of 39,581 shares of Arcus Biosciences common stock, including the unvested component of his Restricted Stock Unit (RSU) grants.

Moreover, he still retains 3,073 stock options, which will become exercisable in 48 equal monthly increments starting from January 1, 2024, provided he continues to serve the company. In addition to this, Arcus Biosciences reported its Q2 2026 financial results, surpassing market expectations. The company reported adjusted earnings of -$0.72 per share, surpassing the forecasted -$0.90 per share, and achieved a significant revenue of $41 million, which exceeded the predicted $22.22 million.

These figures underscore the company's robust financial performance in the quarter. Investors have also taken note of Arcus Biosciences' promising long-term cancer-drug pipeline and its substantial cash reserves, which are expected to endure until at least the second half of 2028. Despite a dip in regular trading, the stock demonstrated a recovery in after-hours trading. These developments underscore the company's ongoing advancements and financial stability.